AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02675777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Intervention
Description: Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)
Study NCT04207073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobilization of median nerve
Description: Neural mobilization
Study NCT03669393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-317 8mg
Description: 3 intravitreal injections of THR-317 8mg, approximately 1 month apart
Study NCT01880450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Prepared
Description: Behavioral intervention to reduce sexual risk and promote healthy relationships
Study NCT01880450 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEEN
Description: Control condition the promote communication, decision-making skills etc.
Study NCT02277171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide impregnated catheter
Description: Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
Study NCT01468519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin via continuous subcutaneous insulin infusion
Study NCT01468519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin via multiple daily injections
Study NCT01535937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg IV over 40 minutes
Study NCT01535937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.025 mg/kg IV over 40 minutes
Study NCT02333838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Thiotepa
Description: IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
Study NCT02333838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Fludarabine
Description: IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
Study NCT02333838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Busulfan
Description: (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
Study NCT01609140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen E, repeating subcutaneous injections every 4 weeks
Study NCT01609140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen D, repeating subcutaneous injections every 4 weeks
Study NCT01609140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen C, repeating subcutaneous injections every 4 weeks
Study NCT01609140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen B, repeating subcutaneous injections every 4 weeks
Study NCT01609140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeating subcutaneous injections of placebo every 4 weeks
Study NCT04607382 — intervention group
Intervention type: DRUG
Intervention: LEP
Description: LEP dosage up to the discretion of the treating gynecologists.
Study NCT04607382 — intervention group
Intervention type: DRUG
Intervention: NSAIDs and/or Chinese medicine (CM)
Description: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
Study NCT02333838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Anti-thymocyte globuline
Description: (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
Study NCT04348903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
Study NCT02603887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02603887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04348903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Pre-Visit Imagery Intervention
Description: Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
Study NCT01984814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
Study NCT00736229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
Study NCT04520789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RPE cell collection and single cell heterogeneity study
Description: Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
Study NCT04520789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RPE cell collection and single cell heterogeneity study
Description: Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
Study NCT04520789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative intervention
Description: Early local steroids drug intervention in patients with severe postoperative PVR
Study NCT04520789 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional Surgery for Retinal Detachment
Description: Conventional Surgery for Retinal Detachment
Study NCT04520789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery for Retinal Detachment
Description: Conventional Surgery for Retinal Detachment
Study NCT04520789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery for Retinal Detachment
Description: Conventional Surgery for Retinal Detachment
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pinaverium
Description: To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Study NCT02330029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atractylodes
Description: Atractylodes (\~10-15g)
Study NCT02330029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paeonia Lactiflora
Description: Paeonia Lactiflora (\~15-30g)
Study NCT02330029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tangerine Peel
Description: Tangerine Peel (\~10g)
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledebouriella Root
Description: Ledebouriella Root (\~10g)
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radix codonopsitis
Description: Radix codonopsitis (\~10-15g)
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radix curcumae
Description: Radix curcumae (\~10g)
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingered citron
Description: Fingered citron (\~10g)
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tuckahoe
Description: Tuckahoe (15g)
Study NCT02330029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is blindly given to patients.
Study NCT00815789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored cardiovascular risk management (Nurse-administered )
Description: A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
Study NCT02167061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01
Description: complex single administration
Study NCT02167061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E+M
Description: co-administration of 2 drugs
Study NCT02167061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 fast
Study NCT02167061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 fed
Study NCT00637728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 110 mg/mL
Description: Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Study NCT00637728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension, 5 mL once daily
Study NCT01901744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Study NCT03823638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral D-Mannitol of Placebo
Description: Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
Study NCT03823638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral D-Mannitol of Placebo
Description: Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
Study NCT03502746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg, IV over 30 minutes.
Study NCT03502746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8mg/kg, IV over 60 minutes.
Study NCT03668132 — intervention group
Intervention type: OTHER
Intervention: ischemic brain damage
Description: Have or not have the ischemic brain damage and the location of the damage
Study NCT01137760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: 5 g of sucrose daily for 8 weeks
Study NCT01137760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide
Description: 2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
Study NCT01137760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide
Description: 5.0 g galactooligosaccharide daily for 8 weeks
Study NCT05132452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)
Description: Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
Study NCT04221152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Tablets
Description: The administration is oral administration with water before or after breakfast.
Study NCT04093284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The needle-free jet injector
Description: Continuous insulin therapy for 9 days
Study NCT02016508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous bone marrow derived stem cells
Description: intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
Study NCT01532375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kochujang
Description: Kochujang (32g/day) for 12weeks.
Study NCT01532375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo(32g/day) for 12weeks
Study NCT00311805 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cells (CD34+)
Description: Intramuscular Injections
Study NCT00311805 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Stem Cells (CD34+)
Description: Intramuscular Injections
Study NCT02663440 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: Hypofractionated IMRT
Study NCT02663440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage Colony-stimulating Factor
Description: Granulocyte-macrophage Colony-stimulating Factor
Study NCT02663440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide
Study NCT02769052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Electrotherapy through self-applied device .
Study NCT01799278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237
Description: MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
Study NCT02846727 — intervention group
Intervention type: DEVICE
Intervention: skin perfusion image
Description: Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
Study NCT02665455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed.
Study NCT03331588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subxiphoid uniportal VATS
Description: Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
Study NCT03331588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal uniportal VATS
Description: The surgical procedures followed principles of pulmonary resections
Study NCT03174275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
Study NCT03174275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
Study NCT03174275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
Study NCT03174275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
Study NCT03174275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical therapy will be at the discretion of the treating surgeon per standard of care.
Study NCT03174275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas
Study NCT04374552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate &Azithromycin
Description: Drug - Hydroxychloroquine sulfate \&Azithromycin
Study NCT04374552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug - placebo
Study NCT02269488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3250
Description: MEDI3250
Study NCT00469729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: StemEx®
Description: The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
Study NCT03166254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: -Pembrolizumab will be given intravenously over the course of 30 minutes
Study NCT03166254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01 vaccine
Description: -Generation of the vaccine is expected to take approximately 12 weeks
Study NCT03166254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
Study NCT03166254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
Study NCT03166254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: -Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
Study NCT03941574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
Study NCT03734159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study NCT00740103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: 60 mg IV x 3 days q 6 - 8 weeks
Study NCT03166254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
Study NCT03734159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study NCT01767389 — intervention group
Intervention type: OTHER
Intervention: The GLP-1 receptor agonist users
Description: The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide